Attached files
| file | filename |
|---|---|
| EX-99.01 - EXHIBIT 99.01 - Inspyr Therapeutics, Inc. | v425403_ex99-01.htm |
| EX-99.02 - EXHIBIT 99.02 - Inspyr Therapeutics, Inc. | v425403_ex99-02.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 23, 2015 (November 20, 2015)
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
| Delaware | 0001421204 | 20-0438951 | ||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Items. |
On November 20, 2015, GenSpera, Inc. (the “Company”) announced interim results from the Phase II study investigating the use of mipsagargin (G-202) for the treatment of glioblastoma multiforme. The results were presented in a poster entitled “Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelial cells, in adult patients with recurrent or progressive glioblastoma,” at the Society for Neuro-Oncology Annual Scientific Meeting in San Antonio, Texas. A copy of the press release and the poster presented are attached to this report as Exhibits 99.01 and 99.02, respectively.
| Item 9.01 | Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|||
|
99.01 99.02 |
Press Release Dated November 20, 2015. Poster Presented at Conference on November 20, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 23, 2015
| GenSpera, Inc. | ||||
| By: | /s/ Craig Dionne | |||
|
Craig Dionne Chief Executive Officer |
||||
INDEX OF EXHIBITS
|
Exhibit No. |
Description |
|||
|
99.01 99.02 |
Press Release Dated November 20, 2015. Poster Presented at Conference on November 20, 2015. |
|||